Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Researchers want to know if irreversible electroporation (IRE) makes it easier for chemotherapy to reach pancreatic cancer cells.
A clinical trial combines epigenetic therapy and immunotherapy to make immunotherapy more effective for patients with pancreatic and bile duct cancers.
Researchers are testing a drug combination of TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, on gastrointestinal cancers.
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Researchers are testing the use of tumor-infiltrating lymphocytes, a type of immunotherapy, against advanced pancreatic cancer.
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
A drug that is epigenetic therapy, which alters how DNA behaves, is being tested in a clinical trial for pancreatic cancer.
Richard Blish was a healthy, athletic 67-year-old when he developed symptoms of pancreatic cancer. His daughter steered him to a clinical trial for treatment.
Researchers are testing two monoclonal antibodies approved to treat melanoma plus radiation as a treatment for pancreatic cancer.